organization · Reporting owner

Bain Capital Fund XIV, L.P.

Disclosed activity across 1 company

Tapewire entity: 52010
SEC CIK: 0002016381

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kailera Therapeutics, Inc.KLRA · Entity 4435	10% owner	April 20, 2026	April 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kailera Therapeutics, Inc.

Report date April 20, 2026 · Filed April 20, 2026

Jointly reported with Bain Capital Investors LLC, Bain Capital XIV General Partner, LLC, BCPE Perseus Investor GP, LLC, BCPE Perseus Investor, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	26,255,581	Last balance in matching sequence After 2026-04-20 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-04-20 · Conversion · Acquired 17,857,143 · Balance 17,857,143 F1: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F2: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F3: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 2 · 2026-04-20 · Purchase · Acquired 8,398,438 · Balance 26,255,581 F2: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F3: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2026-04-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-20 · Conversion · Disposed 17,857,143 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F2: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F3: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

F2: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus").

F3: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 20, 2026 Filed Apr 20, 2026 22:10 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	ConversionSeries B Preferred Stock · Derivative	17,857,143	$0.00	$0.00	Disclosure SEC source: 0001193125-26-164417 · ownership.xml · derivative · entry 3 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner Bain Capital XIV General Partner, LLC · CIK 0002016388 · 10% owner Bain Capital Fund XIV, L.P. · CIK 0002016381 · 10% owner BCPE Perseus Investor GP, LLC · CIK 0002100155 · 10% owner BCPE Perseus Investor, LP · CIK 0002100174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 17,857,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F2 · ownership.nature: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F3 · ownership.nature: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
April 20, 2026 Filed Apr 20, 2026 22:10 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	PurchaseCommon Stock	8,398,438	$16.00	$134,375,008.00	Disclosure SEC source: 0001193125-26-164417 · ownership.xml · nonDerivative · entry 2 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner Bain Capital XIV General Partner, LLC · CIK 0002016388 · 10% owner Bain Capital Fund XIV, L.P. · CIK 0002016381 · 10% owner BCPE Perseus Investor GP, LLC · CIK 0002100155 · 10% owner BCPE Perseus Investor, LP · CIK 0002100174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 26,255,581 F2 · ownership.nature: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F3 · ownership.nature: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
April 20, 2026 Filed Apr 20, 2026 22:10 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	ConversionCommon Stock	17,857,143	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-164417 · ownership.xml · nonDerivative · entry 1 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner Bain Capital XIV General Partner, LLC · CIK 0002016388 · 10% owner Bain Capital Fund XIV, L.P. · CIK 0002016381 · 10% owner BCPE Perseus Investor GP, LLC · CIK 0002100155 · 10% owner BCPE Perseus Investor, LP · CIK 0002100174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 17,857,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F2 · ownership.nature: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F3 · ownership.nature: Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.